Quality. Compliance. Sustainability.

The radiopharmaceutical industry, a strictly regulated domain, is an important segment of healthcare. Monrol UAE made a head start in this field in 2005 and was formalized in 2010. We are proud that we were the first commercial radiopharmaceutical manufacturer to launch in the UAE.

What we do

Monrol UAE manufactures radiopharmaceuticals, a category of drugs used for diagnosing many diseases, including cancers. We believe we play a significant role in the UAE and the region’s oncology environment.

Our objective is to meet the needs of licensed healthcare entities consistently and continually in the UAE and the region by delivering the highest quality radiopharmaceuticals of international standards.

Radioactive tracers are indispensable in oncological diagnosis. We manufacture tracers that assist in diagnosing and managing cancer, including general cancer, bone scans, and prostate cancers, through molecular imaging in a modality called PET (Positron Emission Tomography).

A journey of milestones

In the decade-plus since we launched Monrol UAE, we have achieved many successes guided by our core values of honesty, integrity, uncompromising quality, and safety. Our objective is: Saving Lives.

The joint venture between Mohamed & Obaid AlMulla, Monrol UAE, and Eczacıbaşı-Monrol, the Turkish pharmaceutical giant, signed in 2013, has crossed many milestones.

  • 2010: We manufactured our first tracer, FDG.
  • 2018: Second tracer, 18F-sodium fluoride (18F-NaF), for bone scans.
  • 2020: Third tracer, F-PSMA, for prostate cancer scans.
  • We are researching and developing the fourth tracer for neuroendocrine tumors.
back to top